BOSTON, Feb. 8 /PRNewswire/ -- Surface Logix Inc. announced that Jim
Mahoney, President and Chief Executive Officer, will present an update of
the company's drug development pipeline at the upcoming BIO CEO & Investor
Conference on February 13, 2007, at 4:30 p.m. Eastern time from
Waldorf=Astoria Hotel in New York City.
Surface Logix Inc. currently has two programs in human clinical trials
with a third program approaching its initial regulatory submission. Mr.
Mahoney will discuss the latest results for SLx-2101, currently in Phase
IIa, a second generation PDE5 inhibitor designed to address cardiovascular
indications, including Raynaud's Syndrome and Hypertension; and SLx-4090,
soon to be in Phase IIa, a first-in-class enterocyte specific MTP inhibitor
targeting unmet needs in dyslipidemia, metabolic disorders and obesity.
About Surface Logix Inc.
Surface Logix Inc. uses its expertise in biophysical chemistry to
create new small molecule drugs that are optimized to meet the challenges
of human physiology. The company is advancing multiple internal programs
focused primarily on cardiovascular, metabolic, inflammatory and fibrotic
diseases. For more information, please visit http://www.surfacelogix.com.
Contact:
Warwick Tong MB ChB
Surface Logix Inc.
Senior Vice President, Commercial Development
617.746.8505
Media:
Kari Watson
MacDougall Biomedical Communications Inc.
kwatson@macbiocom.com
508.647.0209
SOURCE Surface Logix Inc.
 back to top
Related links:
http://www.surfacelogix.com
CONTACT:
Warwick Tong MB ChB, Senior Vice President,
Commercial Development of Surface Logix Inc., +1-617-746-8505; or
Media, Kari Watson of MacDougall Biomedical Communications Inc.
for Surface Logix Inc., +1-508-647-0209, or kwatson@macbiocom.com
|
